glycine has been researched along with Minimal Disease, Residual in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "With ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years." | 5.05 | Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. ( Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C, 2020) |
| "Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS)." | 3.01 | Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. ( Alameda, D; Alignani, D; Bargay, J; Blade, J; Burgos, L; Calasanz, MJ; Cedena, MT; Celay, J; Cordón, L; de la Rubia, J; Flores-Montero, J; Fresquet, V; Garcés, JJ; Garcia-Sanz, R; Goicoechea, I; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lara-Astiaso, D; Martin-Sanchez, J; Martinez-Climent, JA; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ramos, MM; Rios, R; Rodriguez, I; Rodriguez, S; Rosiñol, L; San Miguel, J; Sarra, J; Sarvide, S; Vidriales, MB; Vilas-Zornoza, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamond, B | 1 |
| Maclachlan, K | 1 |
| Chung, DJ | 1 |
| Lesokhin, AM | 1 |
| Ola Landgren, C | 1 |
| Goicoechea, I | 1 |
| Puig, N | 1 |
| Cedena, MT | 1 |
| Burgos, L | 1 |
| Cordón, L | 1 |
| Vidriales, MB | 1 |
| Flores-Montero, J | 1 |
| Gutierrez, NC | 1 |
| Calasanz, MJ | 1 |
| Ramos, MM | 1 |
| Lara-Astiaso, D | 1 |
| Vilas-Zornoza, A | 1 |
| Alignani, D | 1 |
| Rodriguez, I | 1 |
| Sarvide, S | 1 |
| Alameda, D | 1 |
| Garcés, JJ | 1 |
| Rodriguez, S | 1 |
| Fresquet, V | 1 |
| Celay, J | 1 |
| Garcia-Sanz, R | 1 |
| Martinez-Lopez, J | 1 |
| Oriol, A | 1 |
| Rios, R | 1 |
| Martin-Sanchez, J | 1 |
| Martinez-Martinez, R | 1 |
| Sarra, J | 1 |
| Hernandez, MT | 1 |
| de la Rubia, J | 1 |
| Krsnik, I | 1 |
| Moraleda, JM | 1 |
| Palomera, L | 1 |
| Bargay, J | 1 |
| Martinez-Climent, JA | 1 |
| Orfao, A | 1 |
| Rosiñol, L | 1 |
| Mateos, MV | 1 |
| Lahuerta, JJ | 1 |
| Blade, J | 1 |
| San Miguel, J | 1 |
| Paiva, B | 1 |
| Striha, A | 1 |
| Ashcroft, AJ | 1 |
| Hockaday, A | 1 |
| Cairns, DA | 1 |
| Boardman, K | 1 |
| Jacques, G | 1 |
| Williams, C | 1 |
| Snowden, JA | 1 |
| Garg, M | 1 |
| Cavenagh, J | 1 |
| Yong, K | 1 |
| Drayson, MT | 1 |
| Owen, R | 1 |
| Cook, M | 1 |
| Cook, G | 1 |
| Syal, R | 1 |
| Reddy S, J | 1 |
| Kumar, R | 1 |
| Tyagi, I | 1 |
| Abrar, AA | 1 |
| Krishnani, N | 1 |
| Mishra, AM | 1 |
| Gupta, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, National, Open-label, Multicenter, Phase III Trial Studying Induction Therapy With Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-dose Chemotherapy With Melphalan-200 (MEL-200) Versus Busulfan-melphalan (BUMEL), and Consol[NCT01916252] | Phase 3 | 460 participants (Anticipated) | Interventional | 2013-09-30 | Completed | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma[NCT03562169] | Phase 3 | 406 participants (Anticipated) | Interventional | 2017-03-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glycine and Minimal Disease, Residual
| Article | Year |
|---|---|
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Prot | 2020 |
2 trials available for glycine and Minimal Disease, Residual
| Article | Year |
|---|---|
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome | 2021 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome | 2021 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome | 2021 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome | 2021 |
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study pro
Topics: Antineoplastic Agents; Boron Compounds; Clinical Trials, Phase III as Topic; Drug Administration Sch | 2018 |
1 other study available for glycine and Minimal Disease, Residual
| Article | Year |
|---|---|
Unusual clinical and MRI features of a cerebellopontine angle medulloepithelioma. Case report and review of literature.
Topics: Brain Chemistry; Cerebellar Neoplasms; Cerebellopontine Angle; Child, Preschool; Choline; Creatine; | 2006 |